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ABSTRACT
Objective: To investigate the cost-effectiveness of
early lens extraction with intraocular lens implantation
for the treatment of primary angle closure glaucoma
(PACG) compared to standard care.
Design: Cost-effectiveness analysis alongside a
multicentre pragmatic two-arm randomised controlled
trial. Patients were followed-up for 36 months, and
data on health service usage and health state utility
were collected and analysed within the trial time
horizon. A Markov model was developed to extrapolate
the results over a 5-year and 10-year time horizon.
Setting: 22 hospital eye services in the UK.
Population: Males and females aged 50 years or over
with newly diagnosed PACG or primary angle closure
(PAC).
Interventions: Lens extraction compared to standard
care (ie, laser iridotomy followed by medical therapy
and glaucoma surgery).
Outcome measures: Costs of primary and secondary
healthcare usage (UK NHS perspective), quality-
adjusted life years (QALYs) and the incremental cost-
effectiveness ratio (ICER) for lens extraction versus
standard care.
Results: The mean age of participants was 67.5
(8.42), 57.5% were women, 44.6% had both eyes
eligible, 1.4% were of Asian ethnicity and 35.4% had
PAC. The mean health service costs were higher in
patients randomised to lens extraction: £2467 vs
£1486. The mean adjusted QALYs were also higher
with early lens extraction: 2.602 vs 2.533. The ICER
for lens extraction versus standard care was £14 284
per QALY gained at three years. Modelling suggests
that the ICER may drop to £7090 per QALY gained by
5 years and that lens extraction may be cost saving by
10 years. Our results are generally robust to changes in
the key input parameters and assumptions.
Conclusions: We find that lens extraction has a
67–89% chance of being cost-effective at 3 years and
that it may be cost saving by 10 years.
Trial registration number: ISRCTN44464607; Results.
INTRODUCTION
Glaucoma has been ranked as the second
most common cause of blindness worldwide
after cataract and is the leading cause of irre-
versible blindness.1 2 A recent study esti-
mated a global prevalence of 3.54% in
people aged 40–80 years, with 64.3 million
individuals estimated to be living with the
condition in 2013. This number is projected
to increase to 76.0 and 111.8 million by 2020
and 2040, respectively.1 There are two main
types of glaucoma: open angle and angle
closure. Although primary open angle glau-
coma (POAG) is more prevalent, primary
angle closure glaucoma (PACG) is more
severe and more likely to result in irrevers-
ible blindness. In PACG, the drainage
pathway at the anterior chamber angle of the
eye is closed leading to increased intraocular
pressure (IOP) which damages the optic
nerve causing vision loss. In an earlier form
Strengths and limitations of this study
▪ The analysis is based on randomised data col-
lected prospectively as part of a pragmatic ran-
domised controlled trial which included 285
participants recruited from 22 healthcare centres
across the UK.
▪ Adequate randomisation and intention to treat
analysis are further strengths of this study,
which enhance the internal and external validity
of our findings.
▪ Estimates of cost-effectiveness beyond three
years rely on extrapolation of the trial data.
▪ As insufficient details were collected to allow for
bottom-up costing of all relevant procedures,
Healthcare Resource Group-based reference
costs were used.
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of the disease, primary angle closure (PAC), there is
increased IOP and an elevated risk of progression but
no evident damage to the optic nerve. PACG is most
prevalent in East Asia. The prevalence of PACG in the
UK adult population (≥40 years old) is 0.4% (ie, there
are about 130 000 patients in the country).3
Demographic risk factors are Chinese race, female
gender and age. Blindness places a high economic
burden on individuals, health systems and society as a
whole,4 and the effect of severe glaucoma on quality of
life is also profound.5
Current treatment for PACG follows a staged approach
involving a combination of laser and medical manage-
ment followed by glaucoma surgery.6 Irrespective of
disease stage at diagnosis, laser iridotomy is the primary
treatment procedure and eye drops are often required
as an adjunct to further reduce the IOP. If treatments
do not sufﬁciently reduce the IOP, then glaucoma
surgery (eg, trabeculectomy) is indicated. However, glau-
coma surgery may fail to control the condition and com-
plications are more likely than for other types of
glaucoma. The standard approaches to PACG manage-
ment have been noted to have variable success.7 8
Since the lens of the eye plays an important role in
the development of PACG, it has been hypothesised that
early lens extraction by phacoemulsiﬁcation may
improve control of IOP and thus reduce the need for
medications and subsequent glaucoma surgery.9 By
replacing laser iridotomy in the care pathway, lens
extraction may enable patients to maintain better visual
function and health-related quality of life.9 Following
lens extraction, either trabeculectomy and/or use of a
glaucoma drainage device offer follow-up surgical
options for medically uncontrolled glaucoma.
The evidence for the effectiveness and cost-
effectiveness of lens extraction compared to other treat-
ment options for PACG is sparse. Friedman and
Vedula10 conducted a systematic review to assess the
effectiveness of lens extraction for chronic angle closure
glaucoma compared with other interventions. They
found two non-randomised studies of poor quality,
which provided insufﬁcient evidence to assess efﬁcacy in
terms of IOP control. The EAGLE trial was conducted
to assess the clinical and cost-effectiveness of early lens
extraction compared with standard care in individuals
with PAC or PACG (ISRCTN 44464607). Here, we report
on the results of the economic evaluation.
METHODS
Study design
Details of the trial design have been reported in the
study protocol.9 In brief, a parallel group randomised
controlled trial (RCT) was conducted. Patients were
recruited from 30 centres across the UK and 6 other
countries—Malaysia, Singapore, Australia, Taiwan, Hong
Kong and China. In total, 419 individuals were recruited
and randomised (1:1) to early lens extraction (n=208)
or standard care (n=211). The economic analysis adopts
a UK health and social care perspective and is therefore
based on the data from 285 participants recruited from
22 centres across the UK, with 145 randomised to lens
extraction and 140 randomised to standard care
between June 2009 and August 2012.
All eligible patients were identiﬁed by an ophthal-
mologist during their initial consultation. Individuals
aged 50 years or over with newly diagnosed PAC and
IOP ≥30 mm Hg, or PACG either untreated or under
medical treatment for 6 months or less, were considered
eligible. Exclusion criteria included: advanced glaucoma
(determined by either: (1) visual ﬁeld loss (mean devi-
ation (MD) worse than −15 dB) or (2) cup–disc-ratio
≥0.9), previously diagnosed acute angle closure attack
in an otherwise eligible eye, increased surgical risk
(eg, corneal opacity, Fuch’s endothelial dystrophy; pseu-
doexfoliation, previous vitreoretinal surgery, not able to
be positioned to undergo standard technique), symp-
tomatic cataract in either eye (deﬁned as sufﬁcient lens
opacity such that one would normally recommend cata-
ract surgery to relieve visual symptoms), prior cataract
surgery or laser iridotomy in the study eye, axial length
<19 mm (nanophthalmos), secondary angle closure
glaucoma, retinal ischaemia, macular oedema, wet
age-related macular degeneration (AMD) or being med-
ically unﬁt for surgery or completion of the trial.
Random allocation of the patients was performed using
a web-based randomisation application with a minimisa-
tion algorithm that included gender, ethnicity, centre,
diagnosis (PAC or PACG), and one or both eyes eligible.
At each site, patients in the treatment group underwent
phacoemulsiﬁcation and intraocular lens implant within
60 days of randomisation, and those who were rando-
mised to standard care were managed with laser periph-
eral iridotomy (standard practice). For patients with
both eyes eligible, the worst eye (or the patient’s choice
if both eyes were equally affected) was designated the
index eye and underwent treatment ﬁrst. It was speci-
ﬁed that second eligible eyes should receive the same
intervention as the index eye within 60 days. Other sub-
sequent treatments in both eyes (eg, medical therapy,
laser peripheral iridoplasty and glaucoma surgery)
were recorded up to 36 months postrandomisation.
Patients had associated medical treatment (with eye
drops) as needed to control the IOP, but if the disease
was uncontrolled the patient underwent glaucoma
surgery. The type of glaucoma surgery was chosen by
the surgeon. Those randomised to standard care could
undergo lens extraction during the study period only
when indicated clinically for reduced vision (ie, cata-
ract surgery), or if the treating physician felt lens
extraction could help control the IOP after escalation
to maximum medical treatment had failed (ie, glau-
coma surgery). The primary economic outcome was
the incremental cost per quality-adjusted life year
(QALY) gained, with QALYs assessed using the EQ-5D
3 level.11
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Health resource use and costs
Secondary care resource use was collected on case report
forms (CRF). Use of primary care services was collected
from patient questionnaires delivered at baseline, 6, 12,
24 and 36 months. The costs of surgical or non-surgical
procedures were estimated based on data recorded in the
trial CRF combined with national unit cost data for each
speciﬁc procedure (table 1).12 Primary care usage,
including general practitioner (GP) contacts, district/
practice nurse consultations and community optician/
optometrist visits, was valued using published per visit
unit costs.13 The type and dose of medications adminis-
tered to patients was collected at each follow-up time
point. Total medication costs were estimated based on
the type and duration of medical treatment, combined
with the associated unit costs.14 Finally, all cost elements
of the interventions and subsequent health service use
were summed to generate a total cost per patient. All unit
costs were obtained for the ﬁnancial year 2012–2013.
Costs incurred by participants and indirect costs
Participant costs were estimated from responses to the
follow-up questionnaires to 36 months and included self-
purchased healthcare and travel costs associated with
making return visit(s) to NHS healthcare facilities.
Self-purchased healthcare costs included items such as
prescription costs, over the counter medications and
costs associated with spectacle wear. These were calcu-
lated based on the amounts that patients reported
paying for them. Patient travel costs were calculated
based on patient reported modes of travel and asso-
ciated costs, multiplied by the number of visits to each
type of facility. Indirect costs, encompassing time costs
for accessing NHS healthcare and time lost from pro-
ductive activities due to ill health, were estimated based
on the reported times taken to attend appointments and
reported time away from usual activities (eg, paid work,
leisure time, housework). Data on wage rates were taken
from the Department of Work and Pensions and used to
value time lost from paid or unpaid employment.15
Inferred values for housework and leisure time were
obtained from other published sources.16 17
Effectiveness
Effectiveness was measured in terms of QALYs gained.
QALYs were estimated based on participant responses to
Table 1 Main unit costs applied in the analysis
Input variables
Unit
cost (£) Source Details
Interventions
Lens extraction
implemented as day case
866 National schedule of reference
costs year 2012–2013
Phacoemulsification cataract extraction and lens
implant implemented as day case (BZ02)
Lens extraction
implemented as inpatient
2157 National schedule of reference
costs year 2012–2013
Phacoemulsification cataract extraction and lens
implant implemented as inpatient (BZ02)
Laser iridotomy
implemented as outpatient
118 National schedule of reference
costs year 2012–2013
Laser iridotomy (minor glaucoma procedures
implemented as outpatient (BZ19))
Subsequent procedures
Lens capsulotomy 121 National schedule of reference
costs year 2012–2013
Lens capsulotomy (BZ04) implemented as
outpatient
Iridoplasty 172 National schedule of reference
costs year 2012–2013
Major glaucoma procedures implemented as
outpatient (BZ17)
Trabeculectomy 1140 National schedule of reference
costs year 2012–2013
Intermediate glaucoma procedures implemented
as day case (BZ18)
Cataract surgery 866 National schedule of reference
costs year 2012–2013
Phacoemulsification cataract extraction and lens
implant implemented as day case (BZ02)
Primary healthcare
General practitioner visit 43 PSSRU 2013 Community-based healthcare staff
General practitioner visit at
home
53.58 PSSRU 2013 Community-based healthcare staff
General practitioner
telephone conversation
26 PSSRU 2013 Community-based healthcare staff
Community optician and
optometrist
62 National schedule of reference
costs year 2012–2013
Follow-up attendance—non-consultant led
outpatient attendances
District nurse 12.40 PSSRU 2013 Community-based healthcare staff
Practice nurse 10.59 PSSRU 2013 Community-based healthcare staff
Clinical support worker
nursing (community)
31 PSSRU 2013 Community-based healthcare staff
Secondary healthcare
Ophthalmologist visit 80 National schedule of reference
costs year 2012–2013
Consultant-led outpatient attendances, follow-up
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the EQ-5D completed at baseline, 6, 12, 24 and
36 months. Reported health status at each time point
was assigned a utility score using the UK population
time trade-off tariff.18 The QALYs for each participant
were calculated by multiplying the time spent in differ-
ent states of health by the utility score associated with
each state, assuming a linear change in utility between
time points. A zero utility weight was assigned from the
time of death for those participants who died during
study follow-up. The Glaucoma Utility Index (GUI) was
also administered as an alternative disease-speciﬁc
preference-based measure of health-related quality of
life.19 The GUI dimensions include central and near
vision; lighting and glare; activities of daily living; mobil-
ity; eye discomfort; and other effects. This instrument
has been scored using a discrete choice experiment con-
ducted on a sample of individuals with glaucoma, pro-
viding a preference-based index value on a scale where
0 is equal to the worst state and 1 is equal to the best
state described by the instrument.
Statistical analysis of trial data
All data were analysed on an intention-to-treat basis
using Stata V.12 (StataCorp. 2011. Stata Statistical
Software: Release 12. College Station TSL). Healthcare
cost and utility data often have several characteristics
that must be addressed through the careful selection of
appropriate statistical analysis methods. In this study, dif-
ferent regression models including generalised linear
models (GLM) with appropriate variance and link func-
tions, seemingly unrelated regression (SUR) and ordin-
ary least square (OLS) were used to estimate the effect
of treatment allocation on costs and QALYs after adjust-
ing for minimisation factors and appropriate prognostic
covariates at baseline (ie, baseline cost and EQ-5D
score). SUR was used for the primary analysis to estimate
between-group differences in mean costs and QALYs,
while accounting for correlation in the error terms. The
method of recycled predictions was used to estimate the
incremental effect of the treatment indicator variable.20
All analyses were also repeated using a multiple imput-
ation (MI) data set (n=20) which was generated using
chained equations to deal with missing cost and utility
data (StataCorp. Stata Multiple-Imputation Reference
Manual Release 12. StataCorp LP: College Station,
2012).
The estimates of mean costs and effects of the two
strategies were compared in an incremental analysis, to
estimate the incremental cost-effectiveness ratio (ICER)
for lens extraction versus standard care. The ICER is cal-
culated as the difference in costs divided by the differ-
ence in effects (QALYs) between two treatments. The
uncertainty surrounding the joint incremental costs and
effects was presented graphically as conﬁdence ellipses
on the incremental cost-effectiveness plane. Since the
ICER has poor statistical properties where differences in
effects are very small, we used the net monetary beneﬁt
(NMB) framework to ascertain the probability of each
strategy being cost-effective at different ceiling ratios
(Rc) representing decision makers’ maximum willing-
ness to pay per QALY gained. The NMB for a given strat-
egy is equal to the mean QALYs accrued multiplied by
Rc, minus the strategy costs.
NMB ¼ ðQALYs Rc) cost ð1Þ
By generating 1000 bootstrapped replicates of the mean
difference in costs and effects, the proportion of repli-
cates favouring each strategy (in terms of mean NMB)
was calculated for a range of plausible values of Rc.
These proportions are interpreted as probabilities of
each strategy being cost-effective at 3 years for the differ-
ent values of Rc. On the basis of the NICE guidance,21
we report these probabilities at ceiling ratios of £20 000
and £30 000 per QALY gained. The mean incremental
NMB (95% CIs) for lens extraction versus standard care
was also plotted against increasing values of Rc. Within
trial subgroup analysis was also conducted to assess how
the estimated ICER varied by disease status (PAC vs
PACG) and one or both eyes eligible for the study.
Markov model for extrapolation of longer term
cost-effectiveness
Although the within trial results provide useful informa-
tion about the cost-effectiveness of lens extraction versus
standard care, the effects of treatment on cumulative
costs and QALYs are expected to persist further into the
future. Therefore, a Markov model was developed to
extrapolate the results of the trial beyond the 3-year
follow-up period to 5 and 10 years (ﬁgure 1). The
model was developed Using TreeAge Pro 2014 (TreeAge
Pro 2014, R1.0. TreeAge Software, Williamstown, MA;
software. http://www.treeage.com) to simultaneously
capture disease progression through glaucoma severity
states and progression to subsequent surgical treatment
(ﬁgure 1). The glaucoma severity states were deﬁned
using cut-offs on the Enhanced Glaucoma Staging
System (GSS 2), which is calculated from two visual ﬁeld
measures: the MD and the pattern SD (PSD).22 The GSS
2 categorises visual ﬁeld damage on a scale from 0 to 16.
We used the modiﬁed visual ﬁeld staging system pro-
posed by Che Hamzah et al23 to create the following
glaucoma severity stages: PAC/normal (0), mild (1–4),
moderate (5–10) and severe (11–16). The probability of
progression was deﬁned as moving down one stage or
more by 36 months. These probabilities were estimated
by baseline severity level and treatment allocation group
using logistic regression on the trial data and trans-
formed into constant 6 month probabilities for use in
the Markov model.
The model structure allows a newly diagnosed cohort
of patients with varying degrees of glaucoma severity to
enter the model and then follow the treatment
sequence described above. The model is updated itera-
tively on a constant 6-month time interval known as the
Markov cycle. The mean age and sex distribution of the
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modelled cohort matched that of the trial participants at
baseline. During each model cycle, a portion of the
cohort progresses in severity (from PAC to mild, mild to
moderate or moderate to severe) based on the probabil-
ities of progression derived from the analysis of the trial
data. Within each model cycle, a proportion of the
cohort also transits to glaucoma or cataract surgery (ie,
trabeculectomy, minimally invasive glaucoma surgeries
(MIGS), Ahmed tube, Zonulo-hyaloido-vitrectomy, clear
lens extraction to control IOP or cataract surgery). This
is based on time-dependent transition probabilities
derived from a Weibull regression of the observed time
to surgery up to 36 months follow-up (see online
supplementary table S1). The Weibull distribution was
selected over other potential candidate distributions
based on the Bayesian information criterion. However,
we also assessed the impact of modelling progression to
surgery using an exponential distribution. Finally, death
from all causes is included in the model as an absorbing
state. Transition probabilities to this state are assumed to
be independent of glaucoma severity and treatment
history and are derived from age/sex speciﬁc UK life
tables.24
Costs are assigned to each state in the model, reﬂect-
ing the mean monitoring and medication costs per
6-month cycle by glaucoma severity and treatment allo-
cation. To populate the model, we disaggregated the
total monitoring and medication costs incurred within
the trial follow-up period to those incurred between
each follow-up time point. This was carried out to best
reﬂect the trend in health services usage over time
following initial intervention. Costs associated with pro-
gression to glaucoma or cataract surgery were incorpo-
rated as transition costs for those modelled to
experience these events. Utility values were also attached
to the modelled severity states by the treatment alloca-
tion group, allowing cumulative model-based QALYs to
be estimated.
Beyond 36 months in the model, we assumed that the
mean cost and utility values (by clinical severity state and
treatment allocation) would be the same as those
incurred between 30 and 36 months. Those modelled to
transit to cataract or glaucoma surgery over follow-up in
the standard care group were modelled to incur the
same health state utility (by severity state) as observed
for those randomised to early lens extraction from that
point onwards in the model.
All model input parameters were deﬁned as statistical
distributions in the model, allowing probabilistic analysis
to be conducted. Ranges and distributional assumptions
for input parameters were based on the trial data and
the literature. We assigned gamma distributions for costs
and β distributions for utility data. We also calculated
correlations between the estimated coefﬁcients for the
variables included in the time-to-event and logistic
regression analyses using Cholesky decomposition and
assigned multinormal distributions to these parameters
in the model to account uncertainty in the estimated
transition probabilities. The analysis was conducted
using second-order Monte Carlo simulation, whereby
the model was analysed 1000 times with a value ran-
domly drawn for each input parameter from its assigned
Figure 1 Structure of the Markov model. PAC, primary angle closure; PACG, primary angle closure glaucoma.
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distribution. By estimating the NMB for each strategy for
each iteration of the probabilistic analysis, cost-
effectiveness acceptability curves were generated. These
present the probability of each strategy being cost-
effective across plausible ranges of Rc. All future costs
and QALYs were discounted using a discount rate of
3.5% per annum.21
Sensitivity analysis
Deterministic sensitivity analysis was conducted to investi-
gate the impact of varying key assumptions and/or par-
ameter values used in the base case analysis. We
explored the impact of the following changes/scenarios:
(1) excluding costs of procedures and medications in
non-eligible eyes; (2) basing the model input parameters
on analysis of the multiple imputation data set; (3)
including indirect and patient costs; (4) using alternative
regression models to estimate the mean cost and utility
parameters (GLM); (5) changing the mean age of the
cohort from 67 to 50 years; (6) adopting different time
horizons and (7) estimating time to glaucoma or cata-
ract surgery using exponential survival regression.
RESULTS
Within trial analysis
The mean age of participants was 67.5 (8.42), 57.5%
were women, 44.6% had bilateral disease with both eyes
eligible for the study, 1.4% were of Asian ethnicity and
35.4% had PAC rather than PACG. Among randomised
patients with one eye eligible for the study, 65% had
bilateral disease but had one eye not eligible according
to the study exclusion criteria. Baseline characteristics
were similar between groups (table 2). Of the 285
patients randomised in the UK, 179 (62.8%) had
complete cost and utility data; 93 (64.14%) in the lens
extraction arm and 86 (61.43%) in the standard care
arm (see online supplementary ﬁgure 1). The remain-
ing participants had missing elements of cost or EQ-5D
data, precluding calculation of total costs or QALYs.
A total of 143 (98.62%) and 139 (99.28) patients
received their intended treatment in the lens extraction
and standard care group, respectively. Healthcare
resource use is summarised in online supplementary
table S2 (supporting data) by the treatment allocation
group. The mean NHS costs were higher in patients ran-
domised to lens extraction; £2474 compared to £1480
(table 4). The mean EQ-5D and GUI utility scores,
unadjusted QALYs and IOP and visual acuity scores are
summarised in table 3. The mean estimated EQ-5D
index at baseline and 36 months was 0.881 (0.850–
0.912) and 0.857 (0.817–0.897) in the lens extraction
group and 0.872 (0.840–0.905) and 0.845 (0.803–0.888)
in the standard care group. The mean estimated QALYs
for patients randomised to lens extraction were 2.602
(2.527–2.672) compared to 2.533 (2.447–2.608) in the
standard care group after adjusting for covariates. The
mean estimated GUI at baseline and 36 months was
0.877 (0.852–0.901) and 0.919 (0.901–0.936) for the
patients in the lens extraction group and 0.874 (0.847–
0.901) and 0.871 (0.845–0.896) for those in the standard
care group.
The analysis of complete case data gives an incremen-
tal cost estimate of £981 (612–1317) for lens extraction
versus standard care, for a mean QALY gain of 0.069
(−0.017–0.159), yielding an ICER of £14 284 per QALY
gained (table 4). On the basis of 1000 bootstrapped esti-
mates of the differences in the mean cost and effects,
lens extraction has a 67% probability of being cost-
effective at 3 years; that is, a 67% probability of
Table 2 Baseline characteristics of participants
Randomised to early lens extraction Randomised to standard care
N=145 N=140
Variables n (%) n (%)
Female 85 (58.62) 79 (56.43)
Both eyes eligible 63 (43.45) 64 (45.71)
Index eye is right 78 (53.79) 80 (57.14)
Chinese 3 (2.07) 1 (0.71)
Diagnosis in index eye
PAC 55 (37.93) 46 (32.86)
PACG 89 (61.38) 94 (67.14)
Missing 1 (0.69) 0 (0)
Mean (SD) Mean (SD)
Age 67.8 (8.48) 67.2 (8.37)
IOP in index eye 29.0 (8.60) 29.7 (7.78)
Visual acuity in index eye 80.5 (11.17) 80.4 (10.84)
Visual acuity in both eyes 84.6 (8.92) 85.6 (7.56)
EQ-5D score 0.881 (0.19) 0.872 (0.19)
Glaucoma Utility Index 0.877 (0.15) 0.874 (0.15)
PAC, primary angle closure; PACG, primary angle closure glaucoma.
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generating the greatest NMB at a ceiling willingness-
to-pay ratio (Rc) of £20 000 per QALY. This increases to
78% for an Rc of £30 000 per QALY. Conﬁdence ellipses
(50%, 75% and 95%) for the joint differences in costs
and effects and the NMB plot for the complete case ana-
lysis are presented in ﬁgure 2.
Considering patient and indirect costs, the mean esti-
mates were £430 (332–553) and £685 (495–933),
Table 3 Health service usage costs and health outcome measures (EQ-5D and Glaucoma Utility Index) by intention to treat
Variables
Randomised to early
lens extraction
Randomised to
standard care
Healthcare cost N £ Mean (SD) N £ Mean (SD)
Initial intervention cost (lens extraction/standard care)
Intervention in eligible eyes 145 1229 (658) 139 181 (77)
Cost of subsequent procedures in eligible eyes
Lens capsulotomy 122 14 (52) 113 0 (0)
Laser iridotomy 122 1 (11) 113 20 (63)
Iridoplasty 122 0 (0) 113 21 (77)
Trabeculectomy 122 19 (145) 113 57 (275)
Cataract surgery 122 28 (155) 113 188 (469)
Other procedures 122 18 (113) 113 45 (276)
Medication cost 122 36 (61) 113 115 (116)
Cost of procedures in non-eligible eyes
Lens capsulotomy 122 2 (15) 113 0 (0)
Laser iridotomy 122 11 (34) 113 67 (70)
Iridoplasty 122 0 (0) 113 3 (23)
Trabeculectomy 122 0 (0) 113 0 (0)
Lens extraction/cataract surgery 122 302 (441) 113 15 (115)
Medication cost 122 13 (31) 113 27 (49)
Primary care costs
GP visits 108 83 (144) 103 117 (223)
Nurse visits 108 27 (58) 102 147 (1115)
Community optician/optometrist visits 108 117 (112) 103 121 (117)
Secondary care costs
Ophthalmology outpatient visits 122 373 (438) 113 407 (390)
Total NHS costs 107 2441 (886) 103 1509 (1389)
Participant cost 105 433 (449) 101 438 (387)
Indirect cost 105 725 (1131) 101 532 (755)
N Mean (SD) N Mean (SD)
EQ-5D values
Baseline 142 0.881 (0.189) 135 0.872 (0.190)
6 months 125 0.903 (0.185) 124 0.847 (0.233)
12 months 130 0.905 (0.159) 120 0.847 (0.232)
24 months 126 0.883 (0.196) 121 0.847 (0.241)
36 months 125 0.857 (0.228) 116 0.845 (0.229)
Total QALYs 96 2.585 (0 0.427) 88 2.526 (0.488)
GUI
Baseline 142 0.877 (0.149) 133 0.874 (0.155)
6 months 126 0.919 (0.094) 127 0.880 (0.138)
12 months 132 0.912 (0.096) 122 0.879 (0.125)
24 months 123 0.916 (0.096) 120 0.878 (0.125)
36 months 128 0.919 (0.102) 122 0.871 (0.142)
Intraocular pressure
Baseline 145 29.0 (8.6) 140 29.7 (7.8)
6 months 139 16.0 (3.9) 134 19.7 (5.3)
12 months 138 16.2 (3.3) 128 18.8 (4.4)
24 months 138 17.3 (4.2) 124 19.1 (5.0)
36 months 130 16.9 (3.8) 124 18.1 (3.8)
Visual acuity (ETDRS)
Baseline 145 80.5 (11.2) 135 80.4 (10.8)
12 months 129 83.0 (7.1) 126 80.9 (11.1)
36 months 129 81.8 (8.4) 122 79.8 (12.2)
GUI, Glaucoma Utility Index; QALY, quality-adjusted life years.
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respectively, for patients randomised to lens extraction,
compared to £479 (372–576) and £489 (335–670) for
patients randomised to standard care.
The analysis based on multiple imputation for
missing data suggests that patients randomised to lens
extraction are expected to cost the health service £844
(551–1124) more on average for a mean QALY gain of
0.1 (0.016–0.193). The estimated ICER is £8430 per
QALY gained, and the probability of lens extraction
being cost-effective is 88.5% at an Rc of £20 000 per
QALY.
Finally, the incremental cost-effectiveness results are
presented by the diagnosis group and by one or both
eyes eligible in table 5. The mean incremental costs and
QALYs for lens extraction versus standard care in
patients with PAC were £1046 (611–1513) and 0.078
Table 4 Incremental cost-effectiveness measures (within trial analysis)
Probability
cost-effective at
Rc
Data Intervention Cost (£) ΔCost (£) QALY ΔQALY ICER (ΔCost/ ΔQALY) (£) £20 000 £30 000
Complete case* Standard care 1486 981 2.533 0.069 14 284 0.671 0.776
Lens extraction 2467 2.602
Multiple imputation Standard care 1567 844 2.442 0.100 8430 0.885 0.940
Lens extraction 2411 2.542
*179 of 285 (93 (64.14%) in the lens extraction and 86 (61.43%) in the standard care group) UK participants have complete cost and QALY
data—above regression results are based on the data of these complete cases.
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life years; Rc, ceiling ratio of willingness to pay per QALY gained.
Figure 2 Confidence ellipses and NMB plot. NMB, net monetary benefit.
Table 5 Incremental cost-effectiveness measures by diagnosis subgroups based on complete case* data (within trial
analysis)
Probability
cost-effective at
Rc
Subgroup Intervention Cost (£) ΔCost (£) QALY ΔQALY ICER (ΔCost/ΔQALY) (£) £20 000 £30 000
PAC Standard care 1374 1046 2.553 0.078 13 401 0.661 0.742
Lens extraction 2420 2.631
PACG Standard care 1535 963 2.522 0.067 14 462 0.620 0.713
Lens extraction 2497 2.589
One eye eligible Standard care 1397 915 2.595 0.004 209 173 0.244 0.317
Lens extraction 2312 2.600
Both eyes eligible Standard care 1595 1099 2.450 0.162 6765 0.901 0.938
Lens extraction 2695 2.613
*179 of 285 (93 (64.14%) in the lens extraction and 86 (61.43%) in the standard care group) UK participants have complete cost and QALY
data—above regression results are based on the data of these complete cases.
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life years; Rc, ceiling ratio of willingness to pay per QALY gained.
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(−0.057–0.203), respectively, whereas the corresponding
ﬁgures were £963 (468–1421) and 0.067 (−0.040–0.190)
among patients with PACG. The estimated ICERs in
patients with PAC and PACG were £13 401 and £14 462
per QALY gained, respectively. The mean incremental
costs and QALYs in patients with one eye eligible were
£915 (£348–£1344) and 0.004 (−0.105–0.109), respect-
ively, with a corresponding ICER of £209 173 per QALY
gained. For those with both eyes eligible the incremental
cost was £1099 (£540–£1631) for an estimated QALY
gain of 0.162 (−0.005–0.329), yielding an ICER of £6765
per QALY gained.
Model-based analysis
The model-based estimates of mean costs and QALYs at
3-years indicate that lens extraction is expected to cost
an additional £938 on average for a QALY gain of 0.062
vs standard care, with a corresponding ICER of £15 223
per QALY gained (table 6). The projected incremental
cost and QALY gain associated with lens extraction at 5
years is estimated to be £559 and 0.079, respectively
(ICER=£7090). Running the model over a 10-year time
horizon suggests that lens extraction may dominate
standard care by this time point; that is, result in a lower
net cost to the health system while generating more
QALYs. The model-based probabilities of lens extraction
being cost-effective at 3, 5 and 10 years are 0.695, 0.897
and 0.957, respectively (table 6). Figure 3 presents the
model-based cost-effectiveness acceptability curves based
on the 10-year time horizon.
Sensitivity analysis
Deterministic sensitivity analysis shows that the model-
based ﬁndings are generally robust to the changes exam-
ined. Excluding the costs of procedures and medications
in non-eligible eyes reduced the estimated ICER from
£15 223 to £11 721 at 3 years. Using the multiple imput-
ation data set to parameterise the model, the estimated
ICER for lens extraction dropped to £8267 at 3 years.
The estimated ICER based on a 3-year time horizon
varied from £13 952 to £16 772 for the other remaining
scenarios assessed. Results of all other scenario analyses
are presented in online supplementary table S3.
DISCUSSION
Principal findings
Our results suggest that lens extraction is likely to offer a
cost-effective approach to treatment compared with
standard care in patients with PACG or PAC, especially
over the longer term. Although the initial costs are
higher for patients assigned to lens extraction, these are
partly offset by cost savings associated with fewer subse-
quent procedures (including repeat laser iridotomy, lens
extraction or glaucoma surgery) and lower medication
use over 3 years. On the basis of the Markov modelling,
our results suggest that lens extraction may become a
cost-saving strategy over a 10-year time horizon.
Table 6 Incremental cost-effectiveness measures (model-based analysis)
Probability
cost-effective at
Rc
Time horizon Intervention
Cost
(£)
ΔCost
(£) QALY ΔQALY
ICER (ΔCost/ ΔQALY)
(£) £20 000 £30 000
3-years’ time horizon Standard care 1563 938 2.484 0.062 15 223 0.699 0.887
Lens
extraction
2501 2.546
5-years’ time horizon Standard care 2264 559 3.903 0.079 7090 0.897 0.951
Lens
extraction
2823 3.982
10-years’ time
horizon
Standard care 3481 −123 6.620 0.107 cost saving 0.957 0.961
Lens
extraction
3358 6.727
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life years; Rc, ceiling ratio of willingness to pay per QALY gained.
Figure 3 Model-based cost-effectiveness acceptability curve
for a 10-year time horizon.
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It should be noted that there is a small difference in
the estimated mean costs and QALYs between the within
trial and model-based analyses at 3 years. These differ-
ences are explained partly by the way we used the trial
data to populate our model and also random noise in
the Monte Carlo simulation. A further difference
between the trial and model-based analysis is that the
model references age-speciﬁc and sex-speciﬁc probabil-
ities of death derived from UK life tables, rather than
the observed within trial mortality. This also partly
explains small differences in mean costs and QALYs.
Within trial subgroup analysis indicated that the esti-
mated ICERs are very similar for those with PAC and
PACG. The point estimate of the ICER for patients with
only one eye eligible was considerably higher compared
to the base case ICER. This is driven by a smaller QALY
gain in this subgroup compared to those with two eyes
eligible. However, it should be noted that the interaction
between treatment allocation and QALYs was not signiﬁ-
cant at the traditional 5% type one error level, and so
this may be a chance ﬁnding due to small numbers. In
addition, it should be noted that 65% of ineligible eyes
had established PAC/PACG and were considered ineli-
gible based on the study exclusion criteria (ie, advanced
glaucoma, previously diagnosed acute angle closure
attack, any previous intraocular procedure or laser treat-
ment). The existing pathology in the ineligible eyes of
these patients may have dominated their HRQoL and
limited capacity to detect improvements associated with
treatment to the eligible eye. Thus, the results in this
subgroup are not applicable to patients newly diagnosed
with unilateral disease where the other eye is unaffected.
Such patients would likely go on to develop bilateral
disease (∼90% of eyes of participants in this study were
diagnosed with either PAC or PACG) and so could have
both eyes treated with early lens extraction at the appro-
priate time. Thus, it is not unreasonable to assume that
all patients presenting with newly diagnosed angle
closure glaucoma (unilateral or bilateral) could ultim-
ately see QALY gains in line with those observed for
patients with both eyes eligible in EAGLE.
Strengths and limitations
Health service resource use and utility data were col-
lected prospectively as part of this pragmatic RCT which
included 285 participants recruited from 22 healthcare
centres across the UK. The results of this economic ana-
lysis should therefore be generalisable across the UK
NHS for patients with early or moderate PACG, and
those with PAC and very high IOP (of 30 mm Hg or
more). Furthermore, data were collected on proce-
dures undertaken in both eyes of eligible patients,
which should ensure that the estimated change in costs
with lens extraction versus standard care is reﬂective of
what would be expected if such a policy were adopted
at a national level. Adequate randomisation and inten-
tion to treat analysis are further strengths of this study,
which enhance the internal and external validity of
our ﬁndings. In addition, conducting a parallel model-
based analysis and populating it with data derived from
the trial is another strength. This provided the ﬂexibil-
ity to extrapolate beyond the trial follow-up period for
the purpose of better informing decision-making.
Finally, we conducted sensitivity analysis to provide
information on how the cost-effectiveness of lens
extraction may vary with changes to key parameters
and assumptions.
Nevertheless, our study has some limitations that need
to be considered when interpreting the results. First, as
insufﬁcient details were collected to allow for bottom-up
costing of all relevant procedures, Healthcare Resource
Group (HRG) based reference costs were used. As each
unit cost in the HRG reference costs is for a group of
procedures with slightly different average costs, there is
a chance these could over or underestimate the real cost
of each procedure. However, the applied reference costs
were generally speciﬁc to the glaucoma procedures of
relevance in the EAGLE trial and were also applied by
treatment setting (inpatient, day case, and outpatient)
to maximise precision. Furthermore, the fact that these
reference costs are based on national routine data may
improve generalisability.
Since trial-based economic evaluation requires com-
plete cost and health-related quality of life data across
all follow-up time points, this precluded 37% of patients
being included in the complete case analysis. To address
uncertainty arising from these missing data, we used
multiple imputation based on chained equations to ﬁll
in numerous plausible values for missing cost and utility
elements. This assumes that data are ‘missing at
random’; that is, missingness can be explained by
observed outcomes and variables. It is a more realistic
assumption in many ways than the assumption of com-
plete case analysis, which is that data are ‘missing com-
pletely at random’ (ie, as if a random sample of data
points has been removed). The results of the multiple
imputation (MI) suggest that the complete case analysis
may underestimate the difference in effects between the
alternatives, as a result of those with poorer health out-
comes being less likely to respond to questionnaires
(particularly affecting the standard care group).
To extrapolate the results beyond the trial follow-up
period, we applied constant mean severity state costs
reﬂecting costs of medications and monitoring in year 3
of the trial. However, this is justiﬁed by the fact that
these costs were observed to be fairly constant over the
second and third year of follow-up. In addition, larger
resource use events (subsequent glaucoma or cataract
surgery) were modelled explicitly based on time-
dependent transition probabilities derived from para-
metric survival analysis. This should improve the preci-
sion of cost projections beyond three years in the model.
Finally, due to data collection limitations in the trial we
were not able to account for pharmacist time in our cost
estimations. However, given that the usage of medica-
tions was higher among the standard care group,
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including these costs would further decrease the ICER
in favour of early lens extraction.
Comparison with other studies
Owing to the paucity of studies on the effectiveness and
cost-effectiveness of early lens extraction as an initial
treatment for patients with PACG, it is difﬁcult to
compare our results with other studies. Patients with
acute attacks of angle closure (a rare presentation of the
disease) were excluded in our trial, and thus studies
evaluating lens extraction for acute attacks are not com-
parable.25 26 A review conducted by Trikha et al8 has sug-
gested that lens extraction for PACG is associated with
better IOP control, reduced complication rates and
reduced need for IOP-controlling medications com-
pared to other relevant treatments. These ﬁndings are
in keeping with ours.
Implications and conclusions
The present study indicates that lens extraction has a 67–
89% chance of being cost-effective at 3 years (assuming
willingness to pay value of £20 000 per QALY gained),
and on the basis of extrapolation it may be cost saving by
10 years. Early lens extraction appears likely to offer a
cost-effective approach to treatment in patients with newly
diagnosed PAC or PACG. Further randomised studies
would help to conﬁrm these ﬁndings, and longer term
follow-up of patients enrolled in this study would help to
verify the model-based extrapolations reported here.
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